{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"GDC-0449"},{"type":"ChemicalStructureName","name":"2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide"},{"type":"Synonym","name":"Hedgehog antagonist GDC-0449"},{"type":"USBrandName","name":"Erivedge"},{"type":"CASRegistryName","name":"879085-55-9"}],"definition":{"html":"An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.","text":"An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/vismodegib","text":"Vismodegib"},"nciConceptId":"C74038","nciConceptName":"Vismodegib","termId":586417,"name":"vismodegib","firstLetter":"v","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"vismodegib"}],"links":null}